The previously announced scientific publication by Diamyd Medical has now been published and is available here:
https://link.springer.com/content/pdf/10.1007/s00125-026-06875-3.pdf
"Times for insulin-dependent autoimmune diabetes are about to change." says Anders Essen-Möller, CEO of Diamyd Medical. "While we do not yet prevent type 1 diabetes, the published data show that retogatein delayed the need for insulin by 5.6 years in the treatment responder group. This has the potential to be truly game-changing. Importantly, retogatein has demonstrated a favourable safety profile and is simple to administer, requiring only two injections. As an antigen-specific therapy, it represents a precision medicine approach to delaying the onset of insulin-dependent type 1 diabetes."
About DiAPREV-IT
DiAPREV-IT (EudraCT 2008-007484-16) evaluated primarily the safety of two subcutaneous injections of retogatein-alum (vs placebo) as well as efficacy in preventing the progression to Stage 3 Type 1 Diabetes in 50 children aged 4-<18 years, positive for GAD autoantibodies and at least one more islet autoantibody and classified as Stage 1 or Stage 2 Type 1 Diabetes, over a 5-year trial period. Results of the trial were published in 2017 in Pediatric Diabetes (https://onlinelibrary.wiley.com/doi/10.1111/pedi.12611).
About Diamyd Medical
Diamyd Medical is a Swedish biotechnology company focused on precision medicine approaches for type 1 diabetes and biological manufacturing. The company's lead investigational drug candidate is retogatein (GAD-alum), based on recombinant GAD65. The Company has established a GMP-approved facility for manufacturing of biological products in Umeå, Sweden. Diamyd Medical's B share is traded on Nasdaq First North Growth Market under the ticker DMYD B. FNCA Sweden AB is the Company's Certified Adviser.